


Spotlight on Ovarian Cancer

Ovarian cancer is a group of diseases that originates in the ovaries, fallopian tubes, or peritoneum (membrane that lines the inside of your abdomen and pelvis).

An estimated 20,890 new cases of ovarian cancer were diagnosed in the U.S. in 2025.

Ovarian cancer mortality has decreased by 45% since 1976, with most of the progress occurring from 2003 through 2023.



Our Impact on Ovarian Cancer Research

We've funded

29 grants totaling \$13.9 million.

V Foundation funded researchers, over their careers, have:

Received

247 grants and over \$4.6 billion in funding.

Produced

over 3,100 publications.

Worked on

54 clinical trials.

V Foundation Funded Researchers – Proven Positive Impact

- **Dipanjan Chowdhury, Ph.D.**, a 2022 Translational Grantee from Dana-Farber Cancer Institute, studies ovarian cancer to improve screening for women at elevated risk of the disease.
- Currently, there are NO screening tests for ovarian cancer and current tests tend to detect it once it has already spread, leading to poor prognosis. There is a need for more accessible tests that can routinely be used to assess ovarian cancer risk.
- Dr. Chowdhury and his team developed a new tool using micro-RNAs (tiny molecules inside our cells that act like volume knobs for genes) circulating in the blood to identify increased cancer risk associated with BRCA1 and BRCA2 mutations WITHOUT needing genetic sequencing (which figures out the order of instructions in our DNA and how they compare in healthy vs. diseased cells).
- While this simple blood test is not yet ready for commercial use, Dr. Chowdhury is hopeful it will lead to more accessible and routine screening for ovarian (and breast) cancer risk, which could profoundly impact screening and early detection of high-risk individuals, leading to improved outcomes.



*Dipanjan Chowdhury, Ph.D.,
2022 Translational Grantee*